Skip to main content
main-content
Erschienen in: Medical Oncology 5/2017

01.05.2017 | Original Paper

Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices

verfasst von: Maurice Herring, Lynn Huynh, Mei Sheng Duh, Francis Vekeman, Audrey Tiew, Maureen Neary, Emily Bergsland

Erschienen in: Medical Oncology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Pancreatic neuroendocrine tumors (pNETs) are rare, slow-growing cancers. Optimal treatment of advanced pNETs is unclear. The aim of this study was to examine treatment patterns and preferences among an academic tertiary medical center and community-based oncology practices. Retrospective chart review was performed for patients with newly diagnosed locally advanced, metastatic, or unresectable pNET diagnosed between January 2010 and December 2013 at an academic tertiary cancer center [University of California, San Francisco (UCSF)] or a large network of community oncology practices [Altos Solutions’ OncoEMR database (ALTOS)]. Fifty-four eligible patients (N UCSF = 23; N ALTOS = 31) were identified. Median time to treatment initiation was 1.1 months; median follow-up time was 22.9 months. UCSF patients underwent more lines of therapy than ALTOS patients despite similar follow-up times. UCSF tended toward more invasive treatment than ALTOS. The median time to treatment discontinuation was statistically significantly shorter for patients on chemotherapy than on targeted therapy in the combined UCSF and ALTOS groups (chemotherapy = 2.1 months vs. targeted = 18.6 months, p < 0.001). Treatment patterns and duration for newly diagnosed advanced pNETs vary widely both within and between different practice settings. Further studies are warranted to investigate the significant difference in duration of targeted therapy compared to chemotherapy.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Capozzi M, Caterina I, De Divitis C, et al. Everolimus and pancreatic neuroendocrine tumors (PNETs): activity, resistance and how to overcome it. Int J Surg. 2005;21(Suppl 1):S89–94. Capozzi M, Caterina I, De Divitis C, et al. Everolimus and pancreatic neuroendocrine tumors (PNETs): activity, resistance and how to overcome it. Int J Surg. 2005;21(Suppl 1):S89–94.
2.
Zurück zum Zitat Cloyd JM, Poultsides GA. Non-functional neuroendocrine tumors of the pancreas: advances in diagnosis and management. World J Gastroenterol. 2015;21(32):9512–25. CrossRefPubMedPubMedCentral Cloyd JM, Poultsides GA. Non-functional neuroendocrine tumors of the pancreas: advances in diagnosis and management. World J Gastroenterol. 2015;21(32):9512–25. CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Martin-Perez E, Capdevila J, Castellano D, et al. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE). Neuroendocrinology. 2013;98:156–68. CrossRefPubMed Martin-Perez E, Capdevila J, Castellano D, et al. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE). Neuroendocrinology. 2013;98:156–68. CrossRefPubMed
4.
Zurück zum Zitat Centzone DC, Cinardi N, Giannone G. Surgical resection for neuroendocrine tumors of the pancreas: a fourteen years single institutional observation. Eur Rev Med Pharmacol Sci. 2004;18(Suppl 2):32–5. Centzone DC, Cinardi N, Giannone G. Surgical resection for neuroendocrine tumors of the pancreas: a fourteen years single institutional observation. Eur Rev Med Pharmacol Sci. 2004;18(Suppl 2):32–5.
5.
Zurück zum Zitat Kulke MH, Shah MH, Benson AB 3rd, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Cancer Netw. 2015;13(1):78–108. CrossRef Kulke MH, Shah MH, Benson AB 3rd, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Cancer Netw. 2015;13(1):78–108. CrossRef
6.
Zurück zum Zitat Berardi R, Rinaldi S, Torniai M, et al. Gastrointestinal neuroendocrine tumors: searching the optimal treatment strategy—a literature review. Crit Rev Oncol Hematol. 2016;98:264–74. CrossRefPubMed Berardi R, Rinaldi S, Torniai M, et al. Gastrointestinal neuroendocrine tumors: searching the optimal treatment strategy—a literature review. Crit Rev Oncol Hematol. 2016;98:264–74. CrossRefPubMed
7.
Zurück zum Zitat Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–13. CrossRefPubMed Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–13. CrossRefPubMed
8.
Zurück zum Zitat Deutsch GB, Lee JH, Bilchik AJ. Long-term survival with long acting somatostatin analogues plus aggressive cytoreductive surgery in patients with metastatic neuroendocrine carcinoma. J Am Coll Surg. 2015;221(1):26–36. CrossRefPubMed Deutsch GB, Lee JH, Bilchik AJ. Long-term survival with long acting somatostatin analogues plus aggressive cytoreductive surgery in patients with metastatic neuroendocrine carcinoma. J Am Coll Surg. 2015;221(1):26–36. CrossRefPubMed
9.
Zurück zum Zitat Hallet J, Law CH, Cukier M, et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589–97. CrossRefPubMed Hallet J, Law CH, Cukier M, et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589–97. CrossRefPubMed
11.
Zurück zum Zitat Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol. 2007;46(6):723–34. CrossRefPubMed Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol. 2007;46(6):723–34. CrossRefPubMed
12.
Zurück zum Zitat Campana D, Capurso G, Partelli S, et al. Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. Eur J Nucl Med Mol Imaging. 2013;40:1197–205. CrossRefPubMed Campana D, Capurso G, Partelli S, et al. Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. Eur J Nucl Med Mol Imaging. 2013;40:1197–205. CrossRefPubMed
13.
Zurück zum Zitat Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72. CrossRefPubMed Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72. CrossRefPubMed
14.
Zurück zum Zitat Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557–77. CrossRefPubMedPubMedCentral Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557–77. CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Folkert IW, Hernandez P, Roses RE. Multidisciplinary management of nonfunctional neuroendocrine tumors of the pancreas. World J Gastroenterol. 2016;22(11):3105–16. CrossRefPubMedPubMedCentral Folkert IW, Hernandez P, Roses RE. Multidisciplinary management of nonfunctional neuroendocrine tumors of the pancreas. World J Gastroenterol. 2016;22(11):3105–16. CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Strosberg JR, Cheema A, Weber J, et al. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol. 2011;29(22):3044–9. CrossRefPubMed Strosberg JR, Cheema A, Weber J, et al. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol. 2011;29(22):3044–9. CrossRefPubMed
17.
Zurück zum Zitat Ter-Minassian M, Brooks NV, Brais LK, et al. Association of progression-free survival with overall survival (OS) in patients (pts) with neuroendocrine tumor (NET) treated with somatostatin analogs. J Clin Oncol. 2015; 33(suppl; abstr 4090). Ter-Minassian M, Brooks NV, Brais LK, et al. Association of progression-free survival with overall survival (OS) in patients (pts) with neuroendocrine tumor (NET) treated with somatostatin analogs. J Clin Oncol. 2015; 33(suppl; abstr 4090).
18.
Zurück zum Zitat Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. 4th ed. Lyon: IARC Press; 2010. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. 4th ed. Lyon: IARC Press; 2010.
19.
Zurück zum Zitat Strosberg JR, Nasir A, Hodul P, Kyols L. Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res. 2008;2:113–25. PubMedPubMedCentral Strosberg JR, Nasir A, Hodul P, Kyols L. Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res. 2008;2:113–25. PubMedPubMedCentral
20.
Zurück zum Zitat Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707–12. CrossRefPubMed Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707–12. CrossRefPubMed
Metadaten
Titel
Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices
verfasst von
Maurice Herring
Lynn Huynh
Mei Sheng Duh
Francis Vekeman
Audrey Tiew
Maureen Neary
Emily Bergsland
Publikationsdatum
01.05.2017
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 5/2017
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-017-0927-0

Weitere Artikel der Ausgabe 5/2017

Medical Oncology 5/2017 Zur Ausgabe

Neu im Fachgebiet Onkologie

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.